Cochlear Ltd.
http://www.cochlear.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cochlear Ltd.
Syngene Chief: Large Cap Biopharma Taking China 'Rotation' More Seriously
A material shift in China derisking discussions by big biopharma against the backdrop of the proposed US BIOSECURE Bill is seen presenting opportunities for Syngene, though the tight US biotech funding environment dampened demand for the Indian CRDMO’s R&D services in Q4.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
Adopt Unilever Model, Tech To Prevent ‘India Plus One’ Situation – CRDMO CXOs
CRDMO CXOs sketch a promising landscape for the Indian industry, highlighting technology, scale and talent, particularly millennials and Gen Z, as key factors in a SWOT analysis - while cautioning that a global ‘China plus one’ strategy could turn to a ‘India plus one’ too.
BMS’ Boerner Bets On AI-Driven R&D In India, Points To Potential For MS, Lupus Drugs
Bristol Myers Squibb CEO Christopher Boerner is looking to India to house the the company’s largest R&D site outside of the US, channeling the country's IT expertise to expand its AI-driven small-molecule research. He also wants to bring its drugs to treat multiple sclerosis and Lupus to India.
Company Information
- Industry
-
Medical Devices
- Biomaterials
- Implantable Devices
- Other Names / Subsidiaries
-
- Cochlear Americas
- Entifie Medical Systems Inc.
- Nobel Biocare USA
- Cochlear Bone Anchored Solutions, Sycle, LLC
- Cochlear Malaysia Sdn. Bhd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice